Jing Ji Guan Cha Wang·2025-07-22 05:48Core Viewpoint - The leading medical aesthetics company, Aimeike, has decided to reclaim the exclusive agency rights for the product "Aisufei" in China from *ST Suwu, which previously held the rights through its subsidiary, Datou Medical. This decision has sparked a strong reaction from *ST Suwu, which accuses Aimeike of violating antitrust laws and acting unethically [2][4]. Group 1: Company Actions and Reactions - Aimeike's subsidiary REGEN has terminated the exclusive agency agreement for Aisufei, a regenerative aesthetic injection product, citing violations by Datou Medical [2][4]. - *ST Suwu has publicly condemned Aimeike's actions, claiming they are unethical and calling for government intervention [2][4]. - Aimeike's global market head stated that the termination is a legitimate action to protect their rights and that they refuse to partner with companies that engage in fraudulent activities [5][6]. Group 2: Financial Implications - Aisufei is expected to generate significant revenue, with projected sales of 326 million yuan and a gross profit of 269 million yuan in 2024 [2]. - Following the termination of the agency rights, *ST Suwu's revenue and profits from its medical aesthetics segment are likely to decline significantly in the second half of the year [7]. - Aimeike reported a revenue of 3.026 billion yuan in 2024, with a year-on-year growth of 5.45%, while its net profit saw a slight increase of 2.2% [8]. Group 3: Legal and Regulatory Context - The exclusive agency agreement was originally set to last until August 28, 2032, but Aimeike claims that *ST Suwu's violations justify the termination [3][4]. - The China Securities Regulatory Commission has penalized *ST Suwu for various violations, including inflated revenue reporting, which has raised concerns about its operational integrity [4][5]. - Aimeike has indicated that if disputes arise, they will rely on legal frameworks to resolve them, emphasizing the importance of compliance and ethical conduct in business partnerships [5].